Science & technology
Our pipeline
Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula)

Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula)

COVID-19 Vaccine Details
Therapeutic area
Infectious disease
Status
Technology
Respiratory diseases
COVID-19
 
Authorized*
Matrix-M™ adjuvant
Therapeutic area
Respiratory diseases
Infectious disease
COVID-19
Status
 
Authorized*
Technology
Matrix-M™ adjuvant

About the candidate

On October 3, 2023 the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for active immunization to prevent COVID-19 in individuals aged 12 and older.

Learn more by reading our Press Release.

*Authorized for use in several countries. For the full list of countries where we are authorized, please visit https://novavaxcovidvaccine.com.

Learn more at fda.gov
More about the disease